← All Ladrx CORP filings

Ladrx CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
LADX
Ladrx CORP
10-Q: LadRx Corporation Reports Q1 2025 Results, Focuses on Aldoxorubicin Approval Pathway
LadRx Corporation reports a net loss for Q1 2025 while advancing its strategy for aldoxorubicin approval and LADR technology development.
OTC.Pink
LADX
Ladrx CORP
10-Q: LadRx Corporation Reports Q3 2024 Results, Faces Going Concern Uncertainty Despite Milestone Payment
LadRx Corporation reported a net loss of $1.9 million for the nine months ended September 30, 2024, and faces substantial doubt about its ability to continue as a going concern despite an expected milestone payment.
OTC.Pink
LADX
Ladrx CORP
10-Q: LadRx Corporation Reports Q2 2024 Results, Focuses on LADR7 Clinical Trial
LadRx Corporation reported a net loss for the second quarter of 2024, while advancing its LADR7 drug candidate towards clinical trials.
OTC.Pink
LADX
Ladrx CORP
10-Q: LadRx Corporation Reports Q1 2024 Financial Results, Achieves Milestone Payment
LadRx Corporation reported a net income of $0.2 million for the first quarter of 2024, driven by a milestone payment, while also progressing its LADR technology platform.